No Data
No Data
Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) CEO Da Lin Ye, the Company's Largest Shareholder Sees 17% Reduction in Holdings Value
Tailin (300813.SZ): Wholly-owned subsidiaries have obtained a total of 8 patent certificates.
Gelonghui, September 10th, Tailin Biotech (300813.SZ) announced that its wholly-owned subsidiaries Zhejiang Tailin Analytical Instrument Co., Ltd. (referred to as "Tailin Analytical Instrument"), Zhejiang Tailin Life Science Co., Ltd. (referred to as "Tailin Life Science"), and Zhejiang Tailin Medical Engineering Co., Ltd. (referred to as "Tailin Medical Engineering") have recently obtained 8 patent certificates (including 2 invention patents). The specific situation is as follows:
Tailin Biotech: 2024 Semi-Annual Report Summary
Tailin Biotech: 2024 Semi-Annual Report
Tailin (300813.SZ): The net income in the first half of the year was 6.5821 million yuan, a year-on-year decrease of 71.62%.
Tailin Bio (300813.SZ) announced its semi-annual report for 2024, with a total operating revenue of 0.156 billion yuan during the reporting period, a year-on-year growth of 9.68%; net income attributable to shareholders of the listed company was 6,582.1 million yuan, a year-on-year decrease of 71.62%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 6,090.4 million yuan, a year-on-year decrease of 69.99%; basic earnings per share is 0.06 yuan.
Tailin (300813.SZ) released its performance for the first half of the year, with a net income of 6.5821 million yuan, a decrease of 71.62%.
Tailin (300813.SZ) released its 2024 interim report, with revenue of 0.156 billion...
No Data
No Data